Roche Aktie

305,00 EUR +8,60 EUR +2,90 %

13:46:38

STU

283,60 CHF +7,40 CHF +2,68 %

17:31:16

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.235,36 Mrd. EUR

KGV26,06Div. Rendite3,58%

WKN851311

ISINCH0012032113

SymbolRHHBF

Roche Aktien News

Sortieren:Datum Meistgelesen

19.09.25Roche Holding AGCHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

18.09.25BenzingaRoche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

18.09.25PR NewswireRoche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

18.09.25GlobesRoche to buy 89bio for up to $3.5b

18.09.25Financial TimesSwitzerland’s Roche strikes $3.5bn deal to buy US drugmaker 89bio

18.09.25Roche Holding AGRoche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

16.09.25PR NewswireRoche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

16.09.25ZacksThe Zacks Analyst Blog Highlights Roche, Linde, Disney and Vaso

15.09.25ZacksTop Analyst Reports for Roche, Linde & Walt Disney

05.09.25PR NewswireRoche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

05.09.25Roche Holding AGNew data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

04.09.25Roche Holding AGRoche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

30.08.25Roche Holding AGRoche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

25.08.25Roche Holding AGRoche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

13.08.25ZacksThe Zacks Analyst Blog Highlights Bank of America, Roche, Intuit and TSS

12.08.25ZacksTop Research Reports for Bank of America, Roche & Intuit

01.08.25Roche Holding AGRoche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

28.07.25RTE.ieRoche to investigate whether drug can prevent Alzheimer's

28.07.25Roche Holding AGRoche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

25.07.25Roche Holding AGRoche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU

24.07.25ZacksRoche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well

24.07.25PR NewswireRoche Diagnostics showcases science-driven leadership and innovation at ADLM 2025

24.07.25Financial TimesRoche boss says ‘very easy’ to cut US drug prices by 50%

24.07.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025

23.07.25Roche Holding AGEuropean Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation

22.07.25Roche Holding AGRoche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

21.07.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

30.06.25Roche Holding AGChanges to the Roche Enlarged Corporate Executive Committee

23.06.25Roche Holding AGEarly data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

20.06.25Roche Holding AGRoche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

16.06.25GlobeNewswireRoche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

16.06.25Roche Holding AGRoche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

15.06.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

15.06.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

04.06.25GlobeNewswireRoche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

04.06.25Roche Holding AGRoche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.